Is Ihuman Stock a Good Investment?

Ihuman Investment Advice

To provide specific investment advice or recommendations on Ihuman Inc stock, we recommend investors consider the following general factors when evaluating Ihuman Inc. This will help you to make an informed decision on whether to include Ihuman in one of your diversified portfolios:

Examine Ihuman's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Ihuman's leadership team and their track record. Good management can help Ihuman navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Hotels, Restaurants & Leisure space and any emerging trends that could impact Ihuman's business and its evolving consumer preferences.
Compare Ihuman's performance and market position to its competitors. Analyze how Ihuman is positioned in terms of product offerings, innovation, and market share.
Check if Ihuman pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Ihuman's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Ihuman Inc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ihuman Inc is a good investment.

Sell

Buy

Strong Sell

We provide advice to complement the regular expert consensus on Ihuman. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Ihuman Inc is not overpriced, please check out all Ihuman fundamentals, including its book value per share, total asset, and the relationship between the cash per share and target price . Please also validate Ihuman Inc price to earning to confirm your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Market Performance	Good	Details
Volatility	Very risky	Details
Hype Condition	Stale	Details
Current Valuation	Overvalued	Details
Odds Of Distress	Low	Details
Economic Sensitivity	Responds to the market	Details
Investor Sentiment	Impartial	Details
Analyst Consensus	Strong Buy	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unavailable	Details

Examine Ihuman Stock

Researching Ihuman's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 1.07. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ihuman Inc last dividend was issued on the 27th of March 2024.

To determine if Ihuman is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ihuman's research are outlined below:

	Ihuman Inc appears to be risky and price may revert if volatility continues
	Latest headline from finance.yahoo.com: HRMY Down 10.8 percent in Six Months How Should You Play the Stock

Ihuman Quarterly Cost Of Revenue

75.54 Million

Ihuman uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ihuman Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ihuman's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	29th of March 2024 Upcoming Quarterly Report	View
	31st of December 2023 Next Fiscal Quarter End	View

Earnings surprises can significantly impact Ihuman's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ihuman's investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2021-03-25	2020-12-31	0.0169	0.0733	0.0564	333
2021-12-21	2021-09-30	0.0764	0.15	0.0736	96
2021-06-08	2021-03-31	0.1629	0.0207	-0.1422	87
2021-09-29	2021-06-30	0.2029	0.03	-0.1729	85
2023-03-31	2022-12-31	0.4754	0.66	0.1846	38
2022-06-21	2022-03-31	-0.0888	0.13	0.2188	246
2022-03-24	2021-12-31	0.1131	-0.15	-0.2631	232
2022-09-22	2022-06-30	0.1298	0.4	0.2702	208

Ihuman Target Price Consensus

Ihuman target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Ihuman's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.

One	Strong Buy

Most Ihuman analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Ihuman stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Ihuman Inc, talking to its executives and customers, or listening to those companies' conference calls.

Macroaxis Advice Exposure Valuation

Ihuman Target Price Projection

Ihuman's current and average target prices are 2.73 and 3.78, respectively. The current price of Ihuman is the price at which Ihuman Inc is currently trading. On the other hand, Ihuman's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Ihuman Market Quote on 20th of March 2025

Low Price	2.51	Odds
High Price	2.88	Odds

2.73 Target Price

Analyst Consensus On Ihuman Target Price

Low Estimate	3.44	Odds
High Estimate	4.2	Odds

3.78

Historical

Lowest Forecast 3.44

Target Price 3.78

Highest Forecast 4.2

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Ihuman Inc and the information provided on this page.

Ihuman Analyst Ratings

Ihuman's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Ihuman stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Ihuman's financials, market performance, and future outlook by experienced professionals. Ihuman's historical ratings below, therefore, can serve as a valuable tool for investors.

Know Ihuman's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Ihuman is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ihuman Inc backward and forwards among themselves. Ihuman's institutional investor refers to the entity that pools money to purchase Ihuman's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Citadel Advisors Llc	2024-12-31	47.7 K
Morgan Stanley - Brokerage Accounts	2024-12-31	41.8 K
Rhumbline Advisers	2024-12-31	11.4 K
Crédit Agricole S.a.	2024-12-31	10 K
Bnp Paribas Arbitrage, Sa	2024-12-31	3.5 K
Ubs Group Ag	2024-12-31	3.3 K
State Street Corp	2024-09-30	0.0
Qube Research & Technologies	2024-09-30	0.0
Xtx Topco Ltd	2024-09-30	0.0
Two Sigma Securities, Llc	2024-12-31	0.0

Note, although Ihuman's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ihuman's market capitalization trends

The company currently falls under 'Small-Cap' category with a market capitalization of 136.82 M.

Market Cap

6.65 Billion

Ihuman's profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	0.11	0.12
Return On Capital Employed	0.19	0.18
Return On Assets	0.11	0.12
Return On Equity	0.22	0.21

The company has Net Profit Margin (PM) of 0.11 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.09 %, which signifies that for every $100 of sales, it has a net operating income of $0.09.

Determining Ihuman's profitability involves analyzing its financial statements and using various financial metrics to determine if Ihuman is a good buy. For example, gross profit margin measures Ihuman's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ihuman's profitability and make more informed investment decisions.

Evaluate Ihuman's management efficiency

Ihuman Inc has Return on Asset (ROA) of 0.0348 % which means that for every $100 of assets, it generated a profit of $0.0348. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1136 %, which means that it produced $0.1136 on every 100 dollars invested by current stockholders. Ihuman's management efficiency ratios could be used to measure how well Ihuman manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Ihuman's Return On Tangible Assets are increasing as compared to previous years. The Ihuman's current Return On Assets is estimated to increase to 0.12, while Return On Capital Employed is projected to decrease to 0.18. As of now, Ihuman's Return On Assets are increasing as compared to previous years. The Ihuman's current Asset Turnover is estimated to increase to 1.17, while Total Assets are projected to decrease to under 945.7 M.

	Last Reported	Projected for Next Year
Book Value Per Share	3.14	3.30
Tangible Book Value Per Share	3.07	3.22
Enterprise Value Over EBITDA	25.59	26.87
Price Book Value Ratio	1.14	1.20
Enterprise Value Multiple	0.04	0.04
Price Fair Value	1.14	1.20
Enterprise Value	5.6 B	5.3 B

Examining the leadership quality of Ihuman Inc offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.

Dividend Yield

0.0552

Forward Dividend Yield

0.0552

Beta

0.367

Basic technical analysis of Ihuman Stock

As of the 20th of March, Ihuman retains the Downside Deviation of 4.62, risk adjusted performance of 0.1495, and Market Risk Adjusted Performance of (1.77). Ihuman technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Ihuman's Outstanding Corporate Bonds

Ihuman issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ihuman Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ihuman bonds can be classified according to their maturity, which is the date when Ihuman Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	iHeartCommunications 6375 percent Corp Bond US45174HBC07	View
	iHeartCommunications 8375 percent Corp Bond US45174HBD89	View
	iHeartCommunications 475 percent Corp Bond US45174HBG11	View
	MPLX LP 4875 Corp Bond US55336VAJ98	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	Morgan Stanley 3971 Corp Bond US61744YAL20	View
	Valero Energy Partners Corp Bond US91914JAA07	View

View All Ihuman Corporate Bonds

Understand Ihuman's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Ihuman's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.1495
	Market Risk Adjusted Performance	(1.77)
	Mean Deviation	3.01
	Semi Deviation	3.62
	Downside Deviation	4.62
	Coefficient Of Variation	627.74
	Standard Deviation	4.77
	Variance	22.73
	Information Ratio	0.1729
	Jensen Alpha	0.7178
	Total Risk Alpha	1.15
	Sortino Ratio	0.1785
	Treynor Ratio	(1.78)
	Maximum Drawdown	17.54
	Value At Risk	(4.07)
	Potential Upside	9.49
	Downside Variance	21.32
	Semi Variance	13.11
	Expected Short fall	(3.48)
	Skewness	0.3327
	Kurtosis	5.39

	Risk Adjusted Performance	0.1495
	Market Risk Adjusted Performance	(1.77)
	Mean Deviation	3.01
	Semi Deviation	3.62
	Downside Deviation	4.62
	Coefficient Of Variation	627.74
	Standard Deviation	4.77
	Variance	22.73
	Information Ratio	0.1729
	Jensen Alpha	0.7178
	Total Risk Alpha	1.15
	Sortino Ratio	0.1785
	Treynor Ratio	(1.78)
	Maximum Drawdown	17.54
	Value At Risk	(4.07)
	Potential Upside	9.49
	Downside Variance	21.32
	Semi Variance	13.11
	Expected Short fall	(3.48)
	Skewness	0.3327
	Kurtosis	5.39

Consider Ihuman's intraday indicators

Ihuman intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ihuman stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	10103.06
	Daily Balance Of Power	0.2973
	Rate Of Daily Change	1.04
	Day Median Price	2.7
	Day Typical Price	2.71
	Price Action Indicator	0.09
	Period Momentum Indicator	0.11
	Relative Strength Index	78.97

Ihuman Corporate Filings

6K	26th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
	31st of October 2024 Other Reports	View Verify

Ihuman time-series forecasting models is one of many Ihuman's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ihuman's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Ihuman Stock media impact

Far too much social signal, news, headlines, and media speculation about Ihuman that are available to investors today. That information is available publicly through Ihuman media outlets and privately through word of mouth or via Ihuman internal channels. However, regardless of the origin, that massive amount of Ihuman data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Ihuman news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ihuman relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ihuman's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ihuman alpha.

Ihuman Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Ihuman can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.